Statin use and Pancreatic Cancer: A Meta-analysis of its Association with Incidence in the General Population and Survival in Patients.

IF 1.6 Q4 ONCOLOGY

Journal of Gastrointestinal Cancer Pub Date : 2025-05-17 DOI:10.1007/s12029-025-01238-4

Jibon Kumar Paul, Mahir Azmal, Omar Faruk Talukder, Ajit Ghosh

{"title":"Statin use and Pancreatic Cancer: A Meta-analysis of its Association with Incidence in the General Population and Survival in Patients.","authors":"Jibon Kumar Paul, Mahir Azmal, Omar Faruk Talukder, Ajit Ghosh","doi":"10.1007/s12029-025-01238-4","DOIUrl":null,"url":null,"abstract":"Purpose: Statins have been appearing as a potential anti-cancer agent in numerous studies. The study aimed to unravel the impact of statins in pancreatic cancer in terms of reducing the occurrence (morbidity) and improving survival (mortality).Methods: A comprehensive search of databases was carried out to collect the eligible studies up to July 2024. This meta-analysis evaluates two distinct questions: (1) whether statin use reduces the incidence of pancreatic ductal adenocarcinoma (PDAC) in the general population, and (2) whether statins improve survival among patients diagnosed with PDAC. In total, 39 studies were included in the meta-analysis, comprising 15 case-control studies, 20 cohort studies, three randomized controlled trials, and one non-randomized controlled trial. A generic inverse variance weighted random-effects model was applied to calculate the pooled risk ratio and 95% confidence intervals. Subgroup analyses were performed based on the availability of relevant information.Results: In the total meta-analysis, aggregated results demonstrated a substantial decrease in pancreatic cancer risk in all statin users (RR 0.94; 95% CIs, 0.90-0.97, and p-value = 0.0008). The pooled risk ratio estimate of lipophilic statins was 0.97 (95% CI, 0.87-1.07; P = 0.50; I2 = 0.0%). The estimated pooled risk ratios of long-term and short-term statin use were 0.80 (95% CI, 0.69-0.92; P = 0.002; I2 = 42%) and 0.86 (95% CI, 0.70-1.06; P = 0.15; I2 = 96%), respectively. For long-term and short-term follow-up, the risk ratios were 0.81 (95% CI, 0.70-0.94; P = 0.007; I2 = 55%) and 0.96 (95% CI, 0.90-1.02; P = 0.16; I2 = 26%), respectively. As for the studies collectively, heterogeneity was tested using the Cochrane chi square test (p-value = = 0.40, I2 = 4%). No publication bias was found.Conclusion: The overall outcome of the study indicates that statins might lower the occurrence and increase the survival of PDAC patients.","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"121"},"PeriodicalIF":1.6000,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Gastrointestinal Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12029-025-01238-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Statins have been appearing as a potential anti-cancer agent in numerous studies. The study aimed to unravel the impact of statins in pancreatic cancer in terms of reducing the occurrence (morbidity) and improving survival (mortality).

Methods: A comprehensive search of databases was carried out to collect the eligible studies up to July 2024. This meta-analysis evaluates two distinct questions: (1) whether statin use reduces the incidence of pancreatic ductal adenocarcinoma (PDAC) in the general population, and (2) whether statins improve survival among patients diagnosed with PDAC. In total, 39 studies were included in the meta-analysis, comprising 15 case-control studies, 20 cohort studies, three randomized controlled trials, and one non-randomized controlled trial. A generic inverse variance weighted random-effects model was applied to calculate the pooled risk ratio and 95% confidence intervals. Subgroup analyses were performed based on the availability of relevant information.

Results: In the total meta-analysis, aggregated results demonstrated a substantial decrease in pancreatic cancer risk in all statin users (RR 0.94; 95% CIs, 0.90-0.97, and p-value = 0.0008). The pooled risk ratio estimate of lipophilic statins was 0.97 (95% CI, 0.87-1.07; P = 0.50; I² = 0.0%). The estimated pooled risk ratios of long-term and short-term statin use were 0.80 (95% CI, 0.69-0.92; P = 0.002; I² = 42%) and 0.86 (95% CI, 0.70-1.06; P = 0.15; I² = 96%), respectively. For long-term and short-term follow-up, the risk ratios were 0.81 (95% CI, 0.70-0.94; P = 0.007; I² = 55%) and 0.96 (95% CI, 0.90-1.02; P = 0.16; I² = 26%), respectively. As for the studies collectively, heterogeneity was tested using the Cochrane chi square test (p-value = = 0.40, I² = 4%). No publication bias was found.

Conclusion: The overall outcome of the study indicates that statins might lower the occurrence and increase the survival of PDAC patients.

查看原文本刊更多论文

他汀类药物的使用与胰腺癌：一项与普通人群发病率和患者生存率相关的荟萃分析。

目的：他汀类药物作为一种潜在的抗癌药物已在众多研究中出现。该研究旨在揭示他汀类药物在减少胰腺癌发生（发病率）和提高生存率（死亡率）方面的影响。方法：全面检索数据库，收集截至2024年7月符合条件的研究。本荟萃分析评估了两个不同的问题：(1)他汀类药物的使用是否降低了普通人群中胰腺导管腺癌（PDAC）的发病率；(2)他汀类药物是否提高了PDAC患者的生存率。meta分析共纳入39项研究，包括15项病例对照研究、20项队列研究、3项随机对照试验和1项非随机对照试验。采用通用逆方差加权随机效应模型计算合并风险比和95%置信区间。根据相关信息的可得性进行亚组分析。结果：在总荟萃分析中，汇总结果显示所有他汀类药物使用者的胰腺癌风险显著降低(RR 0.94；95% ci为0.90-0.97，p值= 0.0008)。亲脂性他汀类药物的合并风险比估计为0.97 (95% CI, 0.87-1.07；P = 0.50；I2 = 0.0%)。估计长期和短期他汀类药物使用的合并风险比为0.80 (95% CI, 0.69-0.92；P = 0.002；I2 = 42%)和0.86 (95% CI, 0.70-1.06；P = 0.15；I2 = 96%)。长期和短期随访的风险比为0.81 (95% CI, 0.70-0.94；P = 0.007；I2 = 55%)和0.96 (95% CI, 0.90-1.02；P = 0.16；I2 = 26%)。对于整体研究，采用Cochrane卡方检验检验异质性（p值= 0.40,I2 = 4%）。未发现发表偏倚。结论：该研究的总体结果表明，他汀类药物可能降低PDAC患者的发生率并提高其生存期。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Gastrointestinal Cancer ONCOLOGY-

CiteScore

3.80

自引率

0.00%

发文量

121

期刊介绍： The Journal of Gastrointestinal Cancer is a multidisciplinary medium for the publication of novel research pertaining to cancers arising from the gastrointestinal tract.The journal is dedicated to the most rapid publication possible.The journal publishes papers in all relevant fields, emphasizing those studies that are helpful in understanding and treating cancers affecting the esophagus, stomach, liver, gallbladder and biliary tree, pancreas, small bowel, large bowel, rectum, and anus. In addition, the Journal of Gastrointestinal Cancer publishes basic and translational scientific information from studies providing insight into the etiology and progression of cancers affecting these organs. New insights are provided from diverse areas of research such as studies exploring pre-neoplastic states, risk factors, epidemiology, genetics, preclinical therapeutics, surgery, radiation therapy, novel medical therapeutics, clinical trials, and outcome studies.In addition to reports of original clinical and experimental studies, the journal also publishes: case reports, state-of-the-art reviews on topics of immediate interest or importance; invited articles analyzing particular areas of pancreatic research and knowledge; perspectives in which critical evaluation and conflicting opinions about current topics may be expressed; meeting highlights that summarize important points presented at recent meetings; abstracts of symposia and conferences; book reviews; hypotheses; Letters to the Editors; and other items of special interest, including:Complex Cases in GI Oncology: This is a new initiative to provide a forum to review and discuss the history and management of complex and involved gastrointestinal oncology cases. The format will be similar to a teaching case conference where a case vignette is presented and is followed by a series of questions and discussion points. A brief reference list supporting the points made in discussion would be expected.